Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

High BMI is a well-known risk factor for the development and recurrence of several solid tumours, including CRC. Obesity is associated with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab is the main targeted therapy for inhibiting tumour angiogenesis by blocking the VEGF/...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Faruk Aykan, N., Yildiz, Ibrahim, Sen, Fatma, Kilic, Leyla, Keskin, Serkan, Ciftci, Rumeysa, Karabulut, Senem, Sakar, Burak, Disci, Rian
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer US 2013
נושאים:
Original Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3755215/
https://ncbi.nlm.nih.gov/pubmed/23921648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-013-0679-4
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים